Tumor vascular proteins: groundbreaking as potential new ovarian cancer biomarkers

References

• Maughan K. Specific keynote: in the shadow of illness – supporting women with ovarian cancer. Gynecol. Oncol.88(1 Pt 2), S129–S133 (2003).
   Web of Science ®Google Scholar
• Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J. Clin.49(1), 33–64 (1999).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson B, Goldberg I, Gotlieb WH et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol. Cell Endocrinol.187(1–2), 39–45 (2002).
   PubMed Web of Science ®Google Scholar
• Hoskins WJ. Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins, PA, USA (2000).
   Google Scholar
• Gogoi R, Srinivasan S, Fishman DA. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Rev. Mol. Diagn.6(4), 627–637 (2006).
   PubMed Web of Science ®Google Scholar
• Mok SC, Elias KM, Wong KK et al. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv. Cancer Res.96, 1–22 (2007).
   PubMed Web of Science ®Google Scholar
• Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev. Proteomics4(1), 121–131 (2007).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Brewer M, Zou C et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res.174, 91–100 (2007).
   PubMedGoogle Scholar
• Fishman DA Bozorgi K. The scientific basis for the early detection of early stage epithelial ovarian carcinoma in ovarian cancer. Kluwer Publishers, NY, USA (2001).
   Google Scholar
• Liotta LA, Clair T. Cancer. Checkpoint for invasion. Nature405(6784), 287–288 (2000).
   PubMed Web of Science ®Google Scholar
• Mills GB, Bast RC Jr, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J. Natl Cancer Inst.93(19), 1437–1439 (2001).
   PubMedGoogle Scholar
• Mills GB, Fang X, Lu Y et al. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol. Oncol.88(1 Pt 2), S88–S92 (2003).
   Google Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumour–host interface. Nature411(6835), 375–379 (2001).
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis,8(2), 169–182 (2005).
   Google Scholar
• Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology - mechanism of tumor progression and therapeutic targets. Int. J. Gynecol. Cancer15(5), 710–726 (2005).
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A et al. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin. Oncol.25(7), 852–861 (2007).
   PubMed Web of Science ®Google Scholar
• Espina V, Wulfkuhle JD, Calvert VS et al. Laser-capture microdissection. Nat. Protoc.1(2), 586–603 (2006).
   PubMed Web of Science ®Google Scholar
• Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol.33(2 Suppl. 6), S3–S11 (2006).
   Web of Science ®Google Scholar
• Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J. Intern. Med.260(6), 517–529 (2006).
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A et al. Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol. Ther.5(6), 635–642 (2006).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterms in serum to identify ovarian cancer. Lancet359(9306), 572–577 (2002).
   Google Scholar
• Lopez MF, Mikulskis A, Kuzdzal S et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem.53(6), 1067–1074 (2007).
   PubMed Web of Science ®Google Scholar